Share on LinkedInShare on Twitter

July 6, 2026 04:27 PM EDTUpdated 05:32 PM

Deals

Pharma

Break­ing: Ver­tex makes $10B deal for com­mer­cial en­docrinol­o­gy biotech Cri­net­ics

Kyle LaHucik

Biotech Correspondent

Ver­tex Phar­ma­ceu­ti­cals is mak­ing the largest ac­qui­si­tion in its his­to­ry, beef­ing up its com­mer­cial port­fo­lio with a $10 bil­lion takeover of Cri­net­ics Phar­ma­ceu­ti­cals.

The Mon­day …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER

Think we're worth reading - tell Google.

Confirm Endpoints as a trusted biopharma news source

Confirm on Google

more like this

• CMS pro­pos­es 340B cuts July 6, 2026
• FDA ap­provals out­run staff cuts: 23 nov­el drugs mark the best first half in three years July 6, 2026
• Bris­tol My­ers de­tails Kraza­ti con­fir­ma­to­ry study fail­ure in col­orec­tal can­cer July 6, 2026

ENDPOINTS CAREERS

Senior Director, Licensing Officer

Bayer

Cambridge, MA, USA

view job offer post your job now

TRENDING NOW

Up­dat­ed: An­throp­ic launch­es Claude Sci­ence as a prod­uct for bio­phar­ma, starts own drug pro­grams

John Reed on J&J’s R&D mod­el, re­cent on­col­o­gy deals and pipeline ex­pan­sion po­ten­tial

Ex­clu­sive: House Chi­na pan­el ques­tions Bris­tol My­ers, Pfiz­er and oth­ers on tri­al sites

Roche’s KRAS G12C in­hibitor beats ri­vals in head-to-head Phase 3 study

Bridge­Bio adds $1B as it pre­pares three more drug launch­es

Post-Hoc: Chi­na deals are phar­ma’s new tax in­ver­sions

Read Original at Endpoints News →